intoDNA provides an end-to-end service for DNA break detection using its proprietary STRIDE™ technology, which quantitatively measures free DNA ends and identifies specific types of DNA damage in various biological materials. This technology enables precision biomarker discovery, facilitating informed decision-making in targeted therapeutics development and patient selection.
Funding
$70K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting and quantifying DNA damage often lack the sensitivity and specificity needed for precision biomarker discovery. Existing techniques may not directly measure free DNA ends or accurately identify specific types of DNA damage in diverse biological samples. This limits the ability to make informed decisions in targeted therapeutics development and patient selection.
Solution
intoDNA offers an end-to-end service for DNA break detection, leveraging its proprietary STRIDE™ technology. STRIDE™ directly detects free DNA ends in situ and provides quantitative measurements of DNA damage at the individual lesion level. The technology is compatible with various biological materials, including patient-derived tissue samples. Automated, AI-driven algorithms objectively quantify fluorescent foci, enabling selective detection of single-, double-, or repair protein-associated DNA breaks. This advanced DNA damage analysis facilitates precision biomarker discovery and informed decision-making in targeted therapeutics development and patient selection.
Target Audience
intoDNA serves pharmaceutical companies, biotech firms, and research laboratories seeking advanced DNA damage analysis for targeted therapeutics development and precision medicine.
Features
- Direct detection of free DNA ends in situ
- Quantitative, automated analysis of DNA damage using AI algorithms
- Compatible with diverse biological materials, including patient-derived tissue samples
- Sensitive measurement of DNA damage at the individual lesion level
- Selective detection of single-, double-, or repair protein-associated DNA breaks